Citation:

Wiranti, Oktofa Yudha Sudrajad. "Financial Performance Analysis and Stock Valuation of PT Kimia Farma Tbk" International Research Journal of Economics and Management Studies, Vol. 3, No. 7, pp. 113-122, 2024.

Abstract:

A prominent pharmaceutical company in Indonesia, Kimia Farma, faced a significant revenue decline compared to its industry counterparts in the aftermath of the pandemic. Given the pharmaceutical sector’s pivotal role in driving innovation, economic growth, and public health, it becomes imperative to explore the company’s financial health with the tight government regulatory and market dynamics influencing industry stability. The objective of this study is to determine the fair value of Kimia Farma’s stock and to conduct a comprehensive analysis of its financial performance. The research delves into competitive rivalry within the pharmaceutical industry and examines both internal and external factors that influence impacting Kimia Farma. This research uses a mixed-methods approach combining qualitative and quantitative analyses. Utilising secondary data sourced from annual audited financial reports and publicly available information, the study leverages five years of historical financial statements from 2018 to 2022. Valuation of Kimia Farma’s stock is conducted using both DCF and relative valuation methods. The findings indicate that the calculated value per share of KAEF is approximately Rp. 569, suggesting an overvaluation relative to prevailing market prices at the time of the study. Key independent variables influencing the valuation include Cost of Goods Sold (COGS), Selling, General and Administrative Expenses (SGA), and Weighted Average Cost of Capital (WACC). This study provides actionable insights and strategic recommendations aimed at enhancing Kimia Farma’s operational and financial strategies. These insights are designed to assist stakeholders, particularly investors, in making well-informed decisions based on rigorous data analysis and comprehensive research findings. By addressing the identified challenges and leveraging opportunities, Kimia Farma can potentially strengthen its market position and improve overall financial performance in the dynamic pharmaceutical landscape of Indonesia.

References:

[1] Abdullah, M. N., & Shamsher, R. (2011). A Study on the Impact of PEST Analysis on the Pharmaceutical Sector: The Bangladesh Context. In Journal of Modern Accounting and Auditing (Vol. 7, Issue 12).
[2] Asmirantho dan Oktiviani Kusumah Somantri, E., Asmirantho, E., & Kusumah Somantri, O. (2017). The Effect of Financial Performance on Stock Price at Pharmaceutical Sub-Sector Company Listed in Indonesia Stock Exchange. Jurnal Ilmiah Akuntansi Fakultas Ekonomi, 3(Tahun), 94–107.
[3] Aswath Damodaran. (2012). Investment Valuation: Tools and Techniques for Determining the Value of Any Asset: Vol. 666 Wiley Finance (3rd ed.). John Wiley & Sons.
[4] Atmaja, M. Y. H., & Davianti, A. (2022). Kinerja Keuangan Perusahaan Farmasi BUMN dan Non-BUMN Sebelum dan Selama Pandemi. Owner, 6(3), 1657–1675
[5] Badan Pusat Statistik. (2023). Statistik Indonesia 2023.
[6] Centers for Medicare & Medicaid Services. (2022). National Health Expenditure Data. Https://Www.Cms.Gov/Data-Research/Statistics-Trends-andReports/National-Health-Expenditure-Data/Nhe-Fact-Sheet.
[7] Dalilah, A., & Hendrawan, R. (2021). Valuasi Saham Pada Perusahaan Sub-Sektor Farmasi dengan Metode Discounted Cash Flow dan Relative Valuation Pada Periode 2013-2020. E-Proceeding of Management, 8(5).
[8] Deloitte. (2022). Dynamics in healthcare post-COVID-19. Https://Www2.Deloitte.Com/Xe/En/Pages/about-Deloitte/Articles/DynamicEvolution/Dynamics-in-Healthcare-Post-Covid-19.Html
[9] Devi, S., Warasniasih, N. M. S., & Masdiantini, P. R. (2020). The Impact of COVID-19 Pandemic on the Financial Performance of Firms on the Indonesia Stock Exchange. Journal of Economics, Business, & Accountancy Ventura, 23(2). https://doi.org/10.14414/jebav.v23i2.2313
[10] Endri, E., Susanti, D., Hutabarat, L., Simanjuntak, T. P., & Handayani, S. (2020). Financial performance evaluation: Empirical evidence of pharmaceutical companies in Indonesia. Systematic Reviews in Pharmacy, 11(6), 803–816. https://doi.org/10.31838/srp.2020.6.117
[11] Fatihudin, D., & Mochklas, M. (2018). How Measuring Financial Performance. International Journal of Civil Engineering and Technology (IJCIET, 9(6), 553–557. http://www.iaeme.com/IJCIET/index.asp553http://www.iaeme.com/ijciet/issues.a sp?JType=IJCIET&VType=9&IType=6http://www.iaeme.com/IJCIET/issues.asp ?JType=IJCIET&VType=9&IType=6
[12] Hilal, M. A. R. (2022). Crisis of Container Ship During Pandemic Lockdown That Affect Stock Valuation of Cargo Transportation and Logistics Company (Case Stude: SMDR) Final Project. Institut Teknologi Bandung.
[13] Ikhwansyah, I., Chandrawulan, A. A., & Amalia, P. (2018). Optimalisasi Peran Badan Usaha Milik Negara (BUMN) pada Era Masyarakat Ekonomi Asean (MEA). Jurnal Media Hukum, 25(2). https://doi.org/10.18196/jmh.2018.0110.150-161
[14] Jagun, C. (2018). Scholar Works Strategies for Compliance with Government Regulations in a Pharmaceutical Company [Walden University]. https://scholarworks.waldenu.edu/dissertations
[15] Kementerian Perindustrian Republik Indonesia. (2019). Perkuat Struktur Industri Farmasi, Pemerintah Fasilitasi Insentif Investasi. Https://Kemenperin.Go.Id/Artikel/20808/Perkuat-Struktur-Industri-Farmasi,- Pemerintah-Fasilitasi-Insentif-Investasi-.
[16] Kyle Peterdy. (2023, May). PESTEL Analysis & Uses in Finance. Https://Corporatefinanceinstitute.Com/Resources/Management/Pestel-Analysis/. https://corporatefinanceinstitute.com/resources/management/pestel-analysis/
[17] Lembaga Ketahanan Nasional RI. (2021). Capaian Program Jaminan Kesehatan. Https://Www.Lemhannas.Go.Id/Index.Php/Berita/Berita-Utama/1173Dirut-Bpjs- Kesehatan-Memberikan-Ceramah-Kepada-Peserta-Ppsa-23.
[18] Mufty, F., Sumirat, E., & Darmansyah, A. (2023). PT Garuda Indonesia (PERSERO) Tbk Stock (GIAA) Fair Value Valuation Post Restructuring and Relisting on IDX. International Journal of Current Science Research and Review, 06(02). https://doi.org/10.47191/ijcsrr/V6-i2-90
[19] Nabila, Z. A., Lubis, C. R. Z., Efvarius, M. R., Apriani, S., & Siahaan, S. D. N. (2023). Analysing Financial Ratios as Indicators to Measure Financial Performance at PT. Industri Jamu dan Farmasi Sido Muncul Tbk. Asian Journal of Applied Business and Management, 2(2), 173–188. https://doi.org/10.55927/ajabm.v2i2.3994
[20] Nedelcheva, Y., & Filipova, M. (2021). Applying the Five Forces Model to Pharmaceutical Industry. Revista Inclusiones, 8(1), 162–173.
[21] Nurbaeti, N., Mirfaqoh, V., Zulhendra, R., Amin, Y. H., Alhadi, N. C., Fadhil, A., Sitohang, R. H., & Yusriani, S. (2023). Analysis of the Financial Performance of PT Kimia Farma, Tbk (Persero) 2021-2022.
[22] Prayogi, R., & Wandebori, H. (2020). Proposed Strategy for Pharmaceutical Industry (Case Study: PT Bio Farma Persero). European Journal of Business and Management Research, 5(5). https://doi.org/10.24018/ejbmr.2020.5.5.457
[23] Priyanto, S., Suselo, D., study Manajemen Keuangan syariah, P., Ekonomi Dan Bisnis Islam, F., & Sayyid Ali Rahmatullah, U. (2023). Analisis Kinerja Keuangan pada Perusahaan PT Kalbe Farma Tbk. Sebelum dan Sesudah Covid-19. As-Syirkah: Islamic Economics & Finacial Journal, 2(2), 134–140. https://doi.org/10.56672/assyirkah.v2i2.58
[24] PT Kimia Farma Tbk. (2022). PT Kimia Farma Tbk Laporan Tahunan Annual Report Standing Firm, Spearheading the Future Healthcare. www.kimiafarma.co.id
[25] Rathore, Dr. C., Kalita, Dr. J. P., Sharma, Dr. S. C., Tiwari, S., & Agarwal, Dr. P. (2023). Major Driving Forces for The Indian SME Pharmaceutical Industry: Using Porter’s Five Forces Framework for A Comparative Analysis. International Journal of Life Science and Pharma Research, L100– L108. https://doi.org/10.22376/ijlpr.2023.13.4.sp6.l100-l108
[26] Setianingsih, R. (2022). Analisis Kinerja Keuangan PT Kimia Farma TBK Sebelum dan Selama Pandemi COVID-19. Jurnal Akuntansi Dan Bisnis , 8(02), 46–56.
[27] Siddiqui, A. A. (2021). The Use of Pestel Analysis Tool of Quality Management in the Health Care Business and its Advantages. American Journal of Biomedical Science & Research, 14(6), 507–512. https://doi.org/10.34297/ajbsr.2021.14.002046
[28] Spiceland, J. D., N. M. W., & T. W. B. (2018). Intermediate Accounting (10th ed.). McGraw-Hill.
[29] Tefi Alonso. (2023, July 13). Porter’s Five Forces (2023): The Definitive Overview (+ Examples). Https://Www.Cascade.App/Blog/Porters-5-Forces.
[30] Ufairatus Syarifa, H. (2022). Analisis Kinerja Keuangan Perusahaan Farmasi yang Tercatat di Bursa Efek Indonesia di Masa Pandemi COVID-19 [Thesis]. Universitas Islam Indonesia.
[31] Yusmar, Q. C. M. M., Sumirat, E., & Sudrajad, O. Y. (2023). Company Fair Valuation Considering Esg Factor (Case Study: Pt Pertamina Geothermal Energy, Tbk). European Journal of Business and Management Research, 8(5), 95–101. https://doi.org/10.24018/ejbmr.2023.8.5.2086
[32] Zayetri, N., & Yudha Sudrajad, O. (2023). HEALTHCARE COMPANY VALUATION (CASE STUDY OF HOSPITAL ABC). Journal of Economics and Business UBS, 12(2).

Keywords:

Discounted Cash Flow, Pharmaceutical, Valuation.